Arthur He
Stock Analyst at HC Wainwright & Co.
(0.71)
# 3,759
Out of 4,826 analysts
61
Total ratings
23.64%
Success rate
-25.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Assumes: Buy | $75 | $23.52 | +218.88% | 1 | May 5, 2025 | |
| ADAG Adagene | Reiterates: Buy | $8 | $1.62 | +393.83% | 10 | Apr 3, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $3.5 → $3 | $0.31 | +876.88% | 6 | Apr 1, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.48 | - | 8 | Mar 31, 2025 | |
| LVTX LAVA Therapeutics | Reiterates: Neutral | $1.5 | $1.20 | +25.52% | 10 | Mar 31, 2025 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $1.40 | +614.29% | 7 | Mar 19, 2025 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $6.5 | $0.65 | +907.75% | 3 | Mar 13, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 → $20 | $3.78 | +429.10% | 9 | Mar 10, 2025 | |
| HOOK HOOKIPA Pharma | Downgrades: Neutral | n/a | $1.35 | - | 7 | Jan 10, 2025 |
Vera Therapeutics
May 5, 2025
Assumes: Buy
Price Target: $75
Current: $23.52
Upside: +218.88%
Adagene
Apr 3, 2025
Reiterates: Buy
Price Target: $8
Current: $1.62
Upside: +393.83%
Adaptimmune Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $0.31
Upside: +876.88%
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.48
Upside: -
LAVA Therapeutics
Mar 31, 2025
Reiterates: Neutral
Price Target: $1.5
Current: $1.20
Upside: +25.52%
Prime Medicine
Mar 19, 2025
Reiterates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
Nektar Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $6.5
Current: $0.65
Upside: +907.75%
Solid Biosciences
Mar 10, 2025
Maintains: Buy
Price Target: $16 → $20
Current: $3.78
Upside: +429.10%
HOOKIPA Pharma
Jan 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -